{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:23:37Z","timestamp":1791894217203,"version":"4.3.4"},"reference-count":157,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.autrev.2015.12.006","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T09:01:07Z","timestamp":1450861267000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"title":["Vitiligo: Pathogenesis, clinical variants and treatment approaches"],"prefix":"10.1016","volume":"15","author":[{"given":"Giannicola","family":"Iannella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Manno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Pasquariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Magliulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2015.12.006_bb0005","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4103\/0378-6323.84059","article-title":"Late onset vitiligo and audiological abnormalities: is there any association?","volume":"77","author":"Al-Mutairi","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0015","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1468-3083.2010.03605.x","article-title":"Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey","volume":"24","author":"Akay","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0020","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/ijd.1978.17.9.755","article-title":"Vitiligo\u2014a retrospect","volume":"17","author":"Nair","year":"1978","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0025","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0738-081X(97)00124-7","article-title":"Historical aspects and definition of vitiligo","volume":"15","author":"Kopera","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1084\/jem.158.1.246","article-title":"Antibodies to normal human melanocytes in vitiligo","volume":"158","author":"Naughton","year":"1983","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2015.12.006_bb0035","first-page":"91","article-title":"Vitiligo and autoimmunity","volume":"67","author":"Kasumagic-Halilovic","year":"2013","journal-title":"Mediev Archaeol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0040","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0738-081X(97)00125-9","article-title":"Pathophysiology of vitiligo","volume":"15","author":"Castanet","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000131485","article-title":"Autoimmune etiology of generalized vitiligo","volume":"10","author":"Le Poole","year":"2008","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.autrev.2015.12.006_bb0050","first-page":"51","article-title":"400 cases of vitiligo. A clinico-therapeutic analysis","volume":"17","author":"Behl","year":"1972","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","article-title":"Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families","volume":"16","author":"Alkhateeb","year":"2003","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archderm.1977.01640010049006","article-title":"Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark","volume":"113","author":"Howitz","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0065","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: a comprehensive overview part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up","volume":"65","author":"Alikhan","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0070","article-title":"Vitiligo. Pathogenesis and treatment","volume":"2","author":"Njoo","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0075","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1468-3083.2007.02228.x","article-title":"Autoimmunity as an aetiological factor in vitiligo","volume":"21","author":"Rezaei","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0080","first-page":"13","article-title":"Occurrence rates of HLA-DRB1, HLA-DQB1, and HLA-DPB1 alleles in patients suffering from vitiligo","volume":"8","author":"Buc","year":"1998","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/jid.2011.240","article-title":"HLA alleles and amino-acid signatures of the peptide-binding pockets of HLA molecules in vitiligo","volume":"132","author":"Singh","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0090","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0625.2012.01473.x","article-title":"Study of CCN3 (NOV) and DDR1 in normal melanocytes and vitiligo skin","volume":"21","author":"Ricard","year":"2012","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0095","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/jid.2010.34","article-title":"Genetic variants of the DDR1 gene are associated with vitiligo in two independent Brazilian population samples","volume":"130","author":"Silva de Castro","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000523","article-title":"Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo","volume":"5","author":"Ren","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.autrev.2015.12.006_bb0105","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa061592","article-title":"NALP1 in vitiligo-associated multiple autoimmune disease","volume":"356","author":"Jin","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.12.006_bb0110","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/sj.jid.5701233","article-title":"PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not","volume":"128","author":"LaBerge","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0115","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.gene.6364243","article-title":"A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo","volume":"6","author":"Cant\u00f3n","year":"2005","journal-title":"Genes Immun"},{"key":"10.1016\/j.autrev.2015.12.006_bb0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00403-002-0295-1","article-title":"Association between catechol-O-methyltransferase polymorphism and vitiligo","volume":"294","author":"T\u00fcrsen","year":"2002","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaad.2003.12.044","article-title":"Characteristics of genetic epidemiology and genetic models for vitiligo","volume":"51","author":"Zhang","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2133.1968.tb12282.x","article-title":"Vitiligo, thyroid disease and autoimmunity","volume":"80","author":"Cunliffe","year":"1968","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0135","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2230.2006.02171.x","article-title":"Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4","volume":"31","author":"Amerio","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0625.2010.01181.x","article-title":"Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo","volume":"20","author":"Kemp","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2249.1997.4781381.x","article-title":"Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2)","volume":"109","author":"Kemp","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0150","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1046\/j.1365-2133.1998.02503.x","article-title":"Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay","volume":"139","author":"Kemp","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2249.1996.d01-727.x","article-title":"Tyrosinase as an autoantigen in patients with vitiligo","volume":"105","author":"Baharav","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0160","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.autrev.2006.03.012","article-title":"Therapeutic implications of autoimmune vitiligo T cells","volume":"5","author":"Oyarbide-Valencia","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.006_bb0165","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1755-148X.2012.01019.x","article-title":"Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells","volume":"25","author":"Zhou","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0170","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0175","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1523-1747.2001.01363.x","article-title":"HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA\/MART1","volume":"116","author":"Lang","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1755-148X.2011.00920.x","article-title":"Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo","volume":"25","author":"Ben Ahmed","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037513","article-title":"Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo","volume":"7","author":"Lili","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2015.12.006_bb0190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autrev.2014.10.002","article-title":"Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics","volume":"14","author":"Dwivedi","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.006_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2015.05.006","article-title":"Posterior reversible encephalopathy syndrome\u2014insight into pathogenesis, clinical variants and treatment approaches","author":"Granata","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.006_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2015.05.005","article-title":"Microscopic polyangiitis: advances in diagnostic and therapeutic approaches","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.006_bb0205","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.autrev.2012.07.012","article-title":"Cogan's syndrome: an autoimmune inner ear disease","volume":"12","author":"Greco","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.006_bb0210","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2133.2009.09217.x","article-title":"Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus","volume":"161","author":"Taher","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0215","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2014.12.003","article-title":"Why treatments do(n't) work in vitiligo: an autoinflammatory perspective","volume":"14","author":"Speeckaert","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.006_bb0220","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1365-2133.2003.05024.x","article-title":"Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo","volume":"148","author":"Gauthier","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0230","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archderm.135.4.407","article-title":"Association of the k\u00f6bner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris","volume":"135","author":"Njoo","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0235","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0749.2003.00070.x","article-title":"A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?","volume":"16","author":"Gauthier","year":"2003","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0240","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2133.1997.18011894.x","article-title":"Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion","volume":"137","author":"Le Poole","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0245","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00403-009-0964-4","article-title":"Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo","volume":"301","author":"Khan","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.jidsp.5640189","article-title":"In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase","volume":"4","author":"Schallreuter","year":"1999","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.autrev.2015.12.006_bb0255","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-4632.2009.03998.x","article-title":"Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo","volume":"48","author":"Dammak","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0260","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4103\/0378-6323.48427","article-title":"Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin","volume":"75","author":"Sravani","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3349\/ymj.2000.41.2.209","article-title":"The classification of segmental vitiligo on the face","volume":"41","author":"Hann","year":"2000","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.autrev.2015.12.006_bb0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0749.1992.tb00003.x","article-title":"Catecholamines and vitiligo","volume":"5","author":"Morrone","year":"1992","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0275","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.8128228","article-title":"Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin","volume":"263","author":"Schallreuter","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.autrev.2015.12.006_bb0280","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jaad.2010.08.031","article-title":"Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients","volume":"65","author":"Ezzedine","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0285","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/abd1806-4841.20142717","article-title":"Vitiligo \u2013 part 2 \u2013 classification, histopathology and treatment","volume":"89","author":"Faria","year":"2014","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0290","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.autrev.2013.01.004","article-title":"Vogt\u2013Koyanagi\u2013Harada syndrome","volume":"12","author":"Greco","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.006_bb0295","first-page":"1057","article-title":"Histopathological studies on cutaneous lesions in sympathetic ophthalmia and Vogt\u2013Koyanagi\u2013Harada syndrome","volume":"65","author":"Ikui","year":"1961","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.autrev.2015.12.006_bb0300","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0190-9622(81)70051-3","article-title":"The prevalence of vitiligo and poliosis in patients with uveitis","volume":"4","author":"Nordlund","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0305","first-page":"478","article-title":"Clinical pattern of ocular manifestations in vitiligo","volume":"101","author":"Biswas","year":"2003","journal-title":"J Indian Med Assoc"},{"key":"10.1016\/j.autrev.2015.12.006_bb0310","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0190-9622(86)70136-9","article-title":"Ocular disturbances in vitiligo","volume":"15","author":"Cowan","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0315","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0161-6420(79)35413-6","article-title":"Ocular abnormalities occurring with vitiligo","volume":"86","author":"Albert","year":"1979","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2015.12.006_bb0320","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2230.2005.02004.x","article-title":"Audiological abnormalities in patients with vitiligo","volume":"31","author":"Aydogan","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0325","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.otohns.2009.11.007","article-title":"Audiological and transient evoked otoacoustic emission findings in patients with vitiligo","volume":"142","author":"Aslan","year":"2010","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.autrev.2015.12.006_bb0330","first-page":"35","article-title":"Audiological manifestations in vitiligo patients","volume":"24","author":"Mahdi","year":"2012","journal-title":"Iran J Otorhinolaryngol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0335","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000350337","article-title":"Risk of sensorineural hearing loss in patients with vitiligo","volume":"18","author":"Fleissig","year":"2013","journal-title":"Audiol Neurootol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0340","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0196-0709(98)90038-2","article-title":"High-frequency hearing and reflex latency in patients with pigment disorder","volume":"19","author":"Ardie","year":"1998","journal-title":"Am J Otol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0345","first-page":"91","article-title":"Evaluation of brain stem evoked response in vitiligo patients","volume":"19","author":"Elsaied","year":"2008","journal-title":"J Pan-Arab League Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0350","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0355","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjd.12111","article-title":"Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners","volume":"168","author":"Teulings","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0360","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D38GS7072J","article-title":"Vitiligo: a good prognostic factor in melanoma?","volume":"15","author":"Cunha","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.autrev.2015.12.006_bb0365","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ced.12531","article-title":"Association between autoimmune disease and cutaneous melanoma with regard to melanoma prognosis","volume":"40","author":"Bottoni","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0370","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0190-9622(83)70182-9","article-title":"Vitiligo in patients with metastatic melanoma: a good prognostic sign","volume":"9","author":"Nordlund","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0375","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02737633","article-title":"The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions","volume":"16","author":"Merimsky","year":"1998","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0380","doi-asserted-by":"crossref","first-page":"684","DOI":"10.18632\/oncotarget.323","article-title":"New perspectives on the role of vitiligo in immune responses to melanoma","volume":"2","author":"Byrne","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.autrev.2015.12.006_bb0385","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.156.6.1755","article-title":"Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets","volume":"156","author":"Houghton","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2015.12.006_bb0390","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1196\/annals.1423.043","article-title":"Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?","volume":"1110","author":"Ram","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2015.12.006_bb0395","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1461::AID-CNCR3>3.0.CO;2-E","article-title":"Autoantibodies to tyrosinase\u2014the bridge between melanoma and vitiligo","volume":"79","author":"Fishman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2015.12.006_bb0400","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0190-9622(86)70260-0","article-title":"Correlation between vitiligo antibodies and extent of depigmentation in vitiligo","volume":"15","author":"Naughton","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0405","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/1097-0142(19931015)72:8<2365::AID-CNCR2820720812>3.0.CO;2-G","article-title":"Vitiligo autoantibodies are effective against melanoma","volume":"72","author":"Fishman","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2015.12.006_bb0410","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s002620050286","article-title":"Anti-tyrosinase antibodies in malignant melanoma","volume":"42","author":"Merimsky","year":"1996","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.autrev.2015.12.006_bb0415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/HAB-1996-7402","article-title":"Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo)","volume":"7","author":"Merimsky","year":"1996","journal-title":"Hum Antibody Hybridomas"},{"key":"10.1016\/j.autrev.2015.12.006_bb0420","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01517212","article-title":"Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism","volume":"38","author":"Merimsky","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.autrev.2015.12.006_bb0425","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/00000421-199612000-00017","article-title":"Melanoma-associated hypopigmentation: where are the antibodies?","volume":"19","author":"Merimsky","year":"1996","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0435","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2015.12.006_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018907","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2015.12.006_bb0445","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","article-title":"Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma","volume":"126","author":"Boasberg","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0450","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.autrev.2015.12.006_bb0455","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2001.19.15.3477","article-title":"Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma","volume":"19","author":"Phan","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0460","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-4362.1983.tb02178.x","article-title":"Histopathology of vitiliginous skin","volume":"22","author":"Gokhale","year":"1983","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0465","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/1523-1747.ep12500086","article-title":"Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo","volume":"79","author":"Moellmann","year":"1982","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0470","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ijd.1993.32.4.269","article-title":"Ultrastructural study of vitiligo","volume":"32","author":"Galadari","year":"1993","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0475","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1529-8019.2008.00178.x","article-title":"Vitiligo: new and emerging treatments","volume":"21","author":"Lotti","year":"2008","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2015.12.006_bb0480","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/1523-1747.ep12476645","article-title":"Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation","volume":"100","author":"Le Poole","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0485","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/DAD.0b013e3181651511","article-title":"Histopathologic features in vitiligo","volume":"30","author":"Kim","year":"2008","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0490","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1346-8138.2010.01139.x","article-title":"Vitiligo: a review of the published work","volume":"38","author":"Yaghoobi","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0495","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MPH.0b013e31826781ad","article-title":"Molecular analysis and clinical findings of Griscelli syndrome patients","volume":"34","author":"Durmaz","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0500","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5482\/HAMO-14-06-0024","article-title":"Hermansky\u2013Pudlak syndrome. Overview of clinical and molecular features and case report of a new HPS-1 variant","volume":"34","author":"S\u00e1nchez-Guiu","year":"2014","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.autrev.2015.12.006_bb0505","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/j.1365-4632.2011.04974.x","article-title":"Hypomelanosis of Ito: pigmentary mosaicism with immature melanosome in keratinocytes","volume":"50","author":"Devillers","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0510","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D385X9M8M1","article-title":"Menkes kinky hair syndrome: a case report","volume":"18","author":"Ghosh","year":"2012","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.autrev.2015.12.006_bb0515","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/2229-5178.96722","article-title":"Piebaldism: a brief report and review of the literature","volume":"3","author":"Agarwal","year":"2012","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.autrev.2015.12.006_bb0520","doi-asserted-by":"crossref","DOI":"10.1111\/pde.12567","article-title":"Tuberous sclerosis complex: an update for dermatologists","author":"Jacks","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2013.03.021","article-title":"Waardenburg syndrome","volume":"88","author":"Carrascosa","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2015.12.006_bb0530","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.autrev.2010.02.013","article-title":"Current remedies for vitiligo","volume":"9","author":"Abu Tahir","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.006_bb0535","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1610-0387.2007.06280.x","article-title":"Current state of vitiligo therapy\u2014evidence-based analysis of the literature","volume":"5","author":"Forschner","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2015.12.006_bb0540","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1517\/14656566.2012.712113","article-title":"Vitiligo: an update on current pharmacotherapy and future directions","volume":"13","author":"Colucci","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.autrev.2015.12.006_bb0545","first-page":"308","article-title":"Vitiligo and intralesional steroids","volume":"69","author":"Vasistha","year":"1979","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0550","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/archderm.134.12.1532","article-title":"Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature","volume":"134","author":"Njoo","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0555","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1755-148X.2008.00528.x","article-title":"Update on skin repigmentation therapies in vitiligo","volume":"22","author":"Falabella","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0560","first-page":"88","article-title":"Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo","volume":"15","author":"Coskun","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0565","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/sj.jid.5700622","article-title":"Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis","volume":"127","author":"Arellano","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0570","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000209289","article-title":"Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma","volume":"219","author":"Schneeweiss","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2015.12.006_bb0575","doi-asserted-by":"crossref","DOI":"10.1111\/pai.12331","article-title":"Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants","author":"Luger","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0580","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archderm.139.5.581","article-title":"A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo","volume":"139","author":"Lepe","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0585","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1346-8138.2008.00511.x","article-title":"Topical immunomodulators are effective for treatment of vitiligo","volume":"35","author":"Choi","year":"2008","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0590","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study","volume":"135","author":"Cavali\u00e9","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0595","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1610-0387.2006.06124.x","article-title":"Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study","volume":"4","author":"Dawid","year":"2006","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2015.12.006_bb0600","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1468-3083.2009.03228.x","article-title":"Pimecrolimus: a new choice in the treatment of vitiligo?","volume":"23","author":"Eryilmaz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0605","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00403-009-0973-3","article-title":"Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus","volume":"302","author":"Lubaki","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2015.12.006_bb0615","first-page":"130","article-title":"Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study","volume":"30","author":"Kawalek","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.autrev.2015.12.006_bb0620","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/pho.2011.3029","article-title":"Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study","volume":"30","author":"Nistic\u00f2","year":"2012","journal-title":"Photomed Laser Surg"},{"key":"10.1016\/j.autrev.2015.12.006_bb0625","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1525-1470.2009.00914.x","article-title":"Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo","volume":"26","author":"Hui-Lan","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0630","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2011.04002.x","article-title":"Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right\/left double-blind comparative study","volume":"25","author":"Nordal","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0635","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1600-0781.2010.00540.x","article-title":"Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study","volume":"26","author":"Majid","year":"2010","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.autrev.2015.12.006_bb0640","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jsps.2012.12.003","article-title":"Methotrexate for the treatment of generalized vitiligo","volume":"21","author":"Alghamdi","year":"2013","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.autrev.2015.12.006_bb0645","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1046\/j.1365-4362.1999.00623.x","article-title":"The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients","volume":"38","author":"Kim","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0650","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1067\/mjd.2001.113475","article-title":"Oral dexamethasone pulse treatment for vitiligo","volume":"44","author":"Radakovic-Fijan","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0655","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1365-4362.2000.00006.x","article-title":"Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo","volume":"39","author":"Seiter","year":"2000","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0660","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jaad.2010.10.043","article-title":"Vitiligo: a comprehensive overview part II: treatment options and approach to treatment","volume":"65","author":"Felsten","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0665","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archderm.1997.03890480045006","article-title":"Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-a","volume":"133","author":"Westerhof","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0670","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archderm.143.5.578","article-title":"Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy","volume":"143","author":"Yones","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0675","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1468-3083.2006.02035.x","article-title":"Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study","volume":"21","author":"Bhatnagar","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0680","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0781.2006.00189.x","article-title":"Narrow band ultraviolet B 311nm in the treatment of vitiligo: two right-left comparison studies","volume":"22","author":"El Mofty","year":"2006","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.autrev.2015.12.006_bb0685","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1034\/j.1600-0781.2001.170403.x","article-title":"PUVA and PUVB in vitiligo\u2014are they equally effective?","volume":"17","author":"Mofty","year":"2001","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.autrev.2015.12.006_bb0690","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","article-title":"Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy","volume":"159","author":"Hearn","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0695","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000018215","article-title":"Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy","volume":"199","author":"Shephard","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2015.12.006_bb0700","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1346-8138.2006.00079.x","article-title":"Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo","volume":"33","author":"Arca","year":"2006","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0705","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-4632.2004.02329.x","article-title":"Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy","volume":"44","author":"Kanwar","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0715","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1365-4632.2004.02014.x","article-title":"Response of vitiligo to PUVA therapy in Saudi patients","volume":"44","author":"Tallab","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0720","first-page":"483","article-title":"Longterm effects of PUVA therapy on Israeli patients with vitiligo","volume":"145","author":"Vussuki","year":"2006","journal-title":"Harefuah"},{"key":"10.1016\/j.autrev.2015.12.006_bb0725","first-page":"983","article-title":"The use of the 308-nm excimer laser for the treatment of vitiligo","volume":"30","author":"Hadi","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.autrev.2015.12.006_bb0730","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1089\/pho.2007.2086","article-title":"Optimal frequency of treatment with the 308-nm excimer laser for vitiligo on the face and neck","volume":"25","author":"Shen","year":"2007","journal-title":"Photomed Laser Surg"},{"key":"10.1016\/j.autrev.2015.12.006_bb0735","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1468-3083.2003.00818.x","article-title":"Monochromatic excimer light 308nm in the treatment of vitiligo: a pilot study","volume":"17","author":"Leone","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0740","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1468-3083.2007.02151.x","article-title":"Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311\u2013313nm) in the treatment of vitiligo\u2014a multicentre controlled study","volume":"21","author":"Casacci","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0745","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1365-4362.2000.00989.x","article-title":"Suction blister grafting for stable vitiligo using pulsed erbium:YAG laser ablation for recipient site","volume":"39","author":"Sachdev","year":"2000","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0750","first-page":"219","article-title":"Treatment of vitiligo with autologous epidermal transplantation using the roofs of suction blisters","volume":"4","author":"Tang","year":"1998","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.autrev.2015.12.006_bb0755","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1001\/archderm.1988.01670110016003","article-title":"Epidermal grafting using the tops of suction blisters in the treatment of vitiligo","volume":"124","author":"Koga","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0760","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1365-4362.1999.00702.x","article-title":"Modified technique of suction blistering for epidermal grafting in vitiligo","volume":"38","author":"Gupta","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0765","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1524-4725.1995.tb00176.x","article-title":"Vitiligo: repigmentation with dermabrasion and thin split-thickness skin graft","volume":"21","author":"Agrawal","year":"1995","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.autrev.2015.12.006_bb0770","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: the European Dermatology Forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0775","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000018089","article-title":"Treatment of stable and recalcitrant vitiligo by autologous miniature punch grafting: a prospective study of 1000 patients","volume":"198","author":"Malakar","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2015.12.006_bb0780","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-4632.2005.02697.x","article-title":"Repigmentation of vitiligo with punch grafting and narrow-band UV-B (311nm)\u2014a prospective study","volume":"45","author":"Lahiri","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0785","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archderm.140.10.1203","article-title":"Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo","volume":"140","author":"van Geel","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0790","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/archderm.140.10.1211","article-title":"Long-term follow-up study of segmental and focal vitiligo treated by autologous, noncultured melanocyte\u2013keratinocyte cell transplantation","volume":"140","author":"Mulekar","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2015.12.006_bb0795","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00005537-200101000-00018","article-title":"Distortion-product otoacoustic emissions and glycerol testing in endolymphatic hydrops","volume":"111","author":"Magliulo","year":"2001","journal-title":"Laryngoscope"},{"key":"10.1016\/j.autrev.2015.12.006_bb0800","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00129492-200303000-00029","article-title":"Preservation of the saccular nerve and of the vestibular evoked myogenic potential during vestibular schwannoma surgery","volume":"24","author":"Magliulo","year":"2003","journal-title":"Otol Neurotol."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215002633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215002633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T09:49:11Z","timestamp":1718272151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997215002633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":157,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1568997215002633"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.12.006","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo: Pathogenesis, clinical variants and treatment approaches","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}